Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: A role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy

Cancer Immunology, Immunotherapy

Volumn 58, Issue 8, 2009, Pages 1219-1228

  Van Der Most, Robbert G ^a,c   Currie, Andrew J ^a   Mahendran, Sathish ^a   Prosser, Amy ^a   Darabi, Anna ^b   Robinson, Bruce W S ^a   Nowak, Anna K ^a   Lake, Richard A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LUND UNIVERSITY   (Sweden)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Chemotherapy; Cyclophosphamide; Gemcitabine; Mesothelioma; Regulatory CD4+ T cells; Tumor immunity

Indexed keywords

B7 ANTIGEN; CYCLOPHOSPHAMIDE; GEMCITABINE; KI 67 ANTIGEN; PROTEIN ICOS; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CD25+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; FEMALE; LOW DRUG DOSE; MESOTHELIOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SUPPRESSOR CELL; T CELL DEPLETION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; L-SELECTIN; LYMPHOCYTE DEPLETION; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY;

EID: 67349250111     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0628-9     Document Type: Article

References (48)

1. MK Andersen A Krarup-Hansen G Martensson H Winther-Nielsen A Thylen K Damgaard S Olling J Wallin 1999 Ifosfamide in malignant mesothelioma: a phase II study Lung Cancer 24 39 43 (Pubitemid 29241816)
2. I Angulo F Gomez de las Heras JF Garcia-Bustos D Gargallo MA Munoz-Fernandez M Fresno 2000 Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER- MP12)+ cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice Blood 95 212 220 (Pubitemid 30017245)
3. M Awwad RJ North 1989 Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells Cancer Res 49 1649 1654 (Pubitemid 19108381)
4. JA Berzofsky M Terabe 2008 NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis J Immunol 180 3627 3635
5. M Beyer JL Schultze 2006 Regulatory T cells in cancer Blood 108 804 811 (Pubitemid 44154611)
6. X Chen JJ Subleski H Kopf OM Howard DN Mannel JJ Oppenheim 2008 Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells J Immunol 180 6467 6471
7. AJ Currie RG van der Most SA Broomfield AC Prosser MG Tovey BW Robinson 2008 Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors J Immunol 180 1535 1544
8. AT den Boer GJ van Mierlo MF Fransen CJ Melief R Offringa RE Toes 2005 CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts Cancer Res 65 6984 6989 (Pubitemid 41065084)
9. LA Emens EM Jaffee 2005 Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res 65 8059 8064 (Pubitemid 41330564)
10. AM Ercolini BH Ladle EA Manning LW Pfannenstiel TD Armstrong JP Machiels JG Bieler LA Emens RT Reilly EM Jaffee 2005 Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 1591 1602 (Pubitemid 40723662)
11. Z Fehervari S Sakaguchi 2004 Development and function of CD25+CD4+ regulatory T cells Curr Opin Immunol 16 203 208
12. I Fernandez R Zeiser H Karsunky N Kambham A Beilhack K Soderstrom RS Negrin E Engleman 2007 CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells J Immunol 179 2808 2814
13. J Gerdes H Lemke H Baisch HH Wacker U Schwab H Stein 1984 Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol 133 1710 1715 (Pubitemid 14035254)
14. F Ghiringhelli N Larmonier E Schmitt A Parcellier D Cathelin C Garrido B Chauffert E Solary B Bonnotte F Martin 2004 CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative Eur J Immunol 34 336 344 (Pubitemid 39255944)
15. F Ghiringhelli C Menard PE Puig S Ladoire S Roux F Martin E Solary A Le Cesne L Zitvogel B Chauffert 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 641 648 (Pubitemid 46348738)
16. RE Gonsette 2007 Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis Expert Opin Pharmacother 8 1103 1116 (Pubitemid 46929303)
17. Haynes NM, van der Most RG, Lake RA, Smyth MJ (2008) Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol
18. JP Hegmans A Hemmes H Hammad L Boon HC Hoogsteden BN Lambrecht 2006 Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses Eur Respir J 27 1086 1095
19. AE Herman GJ Freeman D Mathis C Benoist 2004 CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion J Exp Med 199 1479 1489 (Pubitemid 38780403)
20. M Kleinewietfeld F Puentes G Borsellino L Battistini O Rotzschke K Falk 2005 CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset Blood 105 2877 2886 (Pubitemid 40446282)
21. M Kohyama D Sugahara S Sugiyama H Yagita K Okumura N Hozumi 2004 Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen Proc Natl Acad Sci USA 101 4192 4197 (Pubitemid 38405905)
22. RA Lake BW Robinson 2005 Immunotherapy and chemotherapy-a practical partnership Nat Rev Cancer 5 397 405
23. M Lohning A Hutloff T Kallinich HW Mages K Bonhagen A Radbruch E Hamelmann RA Kroczek 2003 Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10 J Exp Med 197 181 193 (Pubitemid 36152313)
24. ME Lutsiak RT Semnani R De Pascalis SV Kashmiri J Schlom H Sabzevari 2005 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2862 2868 (Pubitemid 40446280)
25. LS Manning D Whitaker AR Murch MJ Garlepp MR Davis AW Musk BW Robinson 1991 Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions Int J Cancer 47 285 290
26. AL Marzo RA Lake BW Robinson B Scott 1999 T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors Cancer Res 59 1071 1079 (Pubitemid 29135968)
27. JD Miller RG van der Most RS Akondy JT Glidewell S Albott D Masopust K Murali-Krishna PL Mahar S Edupuganti S Lalor S Germon C Del Rio MJ Mulligan SI Staprans JD Altman MB Feinberg R Ahmed 2008 Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines Immunity 28 710 722
28. K Movahedi M Guilliams J Van den Bossche R Van den Bergh C Gysemans A Beschin P De Baetselier JA Van Ginderachter 2008 Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity Blood 111 4233 4244
29. DJ Needham JX Lee MW Beilharz 2006 Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy Biochem Biophys Res Commun 343 684 691
30. RJ North M Awwad 1990 Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma Immunology 71 90 95 (Pubitemid 20296077)
31. AK Nowak MJ Byrne MJ Millward JM Alvarez BW Robinson 2004 Current chemotherapeutic treatment of malignant pleural mesothelioma Expert Opin Pharmacother 5 2441 2449 (Pubitemid 39646507)
32. AK Nowak BW Robinson RA Lake 2002 Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy Cancer Res 62 2353 2358 (Pubitemid 34411717)
33. AK Nowak BW Robinson RA Lake 2003 Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Res 63 4490 4496 (Pubitemid 36951021)
34. B Pelaez JA Campillo JA Lopez-Asenjo JL Subiza 2001 Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism J Immunol 166 6608 6615 (Pubitemid 32467201)
35. S Piconese B Valzasina MP Colombo 2008 OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J Exp Med 205 825 839
36. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 267 296 (Pubitemid 46697910)
37. MG Roncarolo S Gregori M Battaglia R Bacchetta K Fleischhauer MK Levings 2006 Interleukin-10-secreting type 1 regulatory T cells in rodents and humans Immunol Rev 212 28 50 (Pubitemid 44116698)
38. G Rudge SP Barrett B Scott IR van Driel 2007 Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells J Immunol 178 4089 4096 (Pubitemid 46492357)
39. AK Simon E Jones H Richards K Wright G Betts A Godkin G Screaton A Gallimore 2007 Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity Eur J Immunol 37 758 767 (Pubitemid 46916942)
40. LA Stephens D Gray SM Anderton 2005 CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity Proc Natl Acad Sci USA 102 17418 17423 (Pubitemid 41740881)
41. L Strauss C Bergmann MJ Szczepanski S Lang JM Kirkwood TL Whiteside 2008 Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression J Immunol 180 2967 2980
42. E Suzuki V Kapoor AS Jassar LR Kaiser SM Albelda 2005 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 6713 6721 (Pubitemid 41339014)
43. J Taieb N Chaput N Schartz S Roux S Novault C Menard F Ghiringhelli M Terme AF Carpentier G Darrasse-Jese F Lemonnier L Zitvogel 2006 Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines J Immunol 176 2722 2729 (Pubitemid 43306930)
44. M Terabe S Matsui JM Park M Mamura N Noben-Trauth DD Donaldson W Chen SM Wahl S Ledbetter B Pratt JJ Letterio WE Paul JA Berzofsky 2003 Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence J Exp Med 198 1741 1752 (Pubitemid 37494166)
45. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, Schlemmer F, Zitvogel L, Kroemer G (2008) Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol
46. S Watanabe K Deguchi R Zheng H Tamai LX Wang PA Cohen S Shu 2008 Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes J Immunol 181 3291 3300
47. G Zhou HI Levitsky 2007 Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance J Immunol 178 2155 2162 (Pubitemid 46233413)
48. L Zitvogel L Apetoh F Ghiringhelli F Andre A Tesniere G Kroemer 2008 The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118 1991 2001